Efficacy and safety of oral pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg twice daily versus oral amoxicillin/clavulanate 1000/125 mg three times daily for the treatment of bacterial community-acquired pneumonia (CAP) Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001
Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011
IV azithromycin (AZM)/ceftriaxone (CEF) followed by PO AZM vs IV levofloxacin (LEV) followed by PO LEV in treatment of hospitalized patients with community acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003
Clinical efficacy of bolus versus continuous-infusion of piperacillin-tazobactam in VAP treatment Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011
Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012
Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare Source: Eur Respir J 2002; 20: Suppl. 38, 561s Year: 2002
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003
Efficacy, safety and tolerability of 3 day azithromycin versus 10-day amoxillin/clavulanic acid in the treatment of children with pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 143s Year: 2003
Pharmacokinetics of consecutive oral moxifloxacin 400 mg/day in patients with respiratory tract infection Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
3-day azithromycin (AZM) 500 mg qd versus 10-day clarithromycin (CLA) 500 mg bid for acute exacerbation of chronic bronchitis (AECB) in adults Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002
Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 674s Year: 2007
Effectiveness and safety of gatifloxacin in patients with drug resistance tuberculosus befor unsuccessfully treated with ofloxacin and ciprofloxacin Source: Eur Respir J 2006; 28: Suppl. 50, 588s Year: 2006
Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP) Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008
PIVOT trial (pneumonia intravenous versus oral treatment) Source: Eur Respir J 2003; 22: Suppl. 45, 141s Year: 2003
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005
A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001
Combination therapy (beta-lactam+macrolide) vs fluoroquinolone monotherapy for the treatment of CAP Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012
Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB Source: Eur Respir J 2013; 41: 1386-1392 Year: 2013
Efficacy of sequential intravenous (i.v. ) to oral (p.o. ) moxifloxacin in hospitalized patients with community-acquired pneumonia (CAP) due to m. pneumoniae or chlamydia spp. Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007